Highland Park, IL, United States of America

Phillip Bauer

USPTO Granted Patents = 2 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Phillip Bauer

Introduction

Phillip Bauer is an accomplished inventor based in Highland Park, IL (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral delivery systems for calcitonin. With a total of two patents to his name, his work has the potential to impact treatment methods for various medical conditions.

Latest Patents

Bauer's latest patents focus on room temperature stable oral calcitonin formulations. These patents disclose room-temperature stable dosage forms for oral delivery of calcitonin, which are crucial for ensuring the stability and efficacy of the medication. The formulations also include low water content dosage forms, which are essential for maintaining the integrity of the active ingredient. Furthermore, the patents outline methods for producing these stable dosage forms and detail treatment methods that involve their administration.

Career Highlights

Throughout his career, Phillip Bauer has worked with notable companies such as Enteris Biopharma, Inc. and Taurus Development Company LLC. His experience in these organizations has allowed him to refine his skills and contribute to innovative pharmaceutical solutions.

Collaborations

Bauer has collaborated with several professionals in his field, including James P. Gilligan and George R. Maurer. These partnerships have likely enhanced his research and development efforts, leading to the successful creation of his patented formulations.

Conclusion

Phillip Bauer's work in developing room temperature stable oral calcitonin formulations showcases his dedication to advancing pharmaceutical innovations. His contributions are poised to make a significant impact on treatment options for patients requiring calcitonin therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…